Holen Sie sich die Stockscreener-App
54.69
3.03%
-1.71
Handel nachbörslich:
54.23
-0.46
-0.84%
Schlusskurs vom Vortag:
$56.40
Offen:
$56.39
24-Stunden-Volumen:
31,013
Relative Volume:
0.74
Marktkapitalisierung:
$1.89B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-32.61M
KGV:
-46.58
EPS:
-1.1742
Netto-Cashflow:
-
1W Leistung:
-6.69%
1M Leistung:
-18.71%
6M Leistung:
-5.05%
1J Leistung:
+63.60%
1-Tages-Spanne:
$53.59
$56.40
1-Wochen-Bereich:
$53.59
$60.21
52-Wochen-Spanne:
$32.50
$86.53
Belite Bio Inc Adr Stock (BLTE) Company Profile
Firmenname
Belite Bio Inc Adr
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie BLTE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BLTE
Belite Bio Inc Adr
|
54.69 | 1.89B | 0 | -32.61M | 0 | -1.1742 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Belite Bio Inc Adr Stock (BLTE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-12-14 | Eingeleitet | Maxim Group | Buy |
| 2023-07-28 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-07-26 | Eingeleitet | SVB Securities | Outperform |
| 2022-08-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-07-01 | Eingeleitet | The Benchmark Company | Buy |
Belite Bio Inc Adr Aktie (BLTE) Neueste Nachrichten
Brokers Offer Predictions for Belite Bio FY2028 Earnings - Defense World
Belite Bio shareholders approve all resolutions at AGM By Investing.com - Investing.com South Africa
Belite Bio Announces Key Resolutions from 2025 General Meeting - TipRanks
Belite Bio shareholders approve all resolutions at AGM - Investing.com
Belite Bio, Inc. Appoints New Auditor - TipRanks
Benchmark Reiterates Buy Rating for Belite Bio (NASDAQ:BLTE) - Defense World
Belite Bio stock target raised to $80 at Benchmark By Investing.com - Investing.com South Africa
Belite Bio price target raised to $80 from $79 at Benchmark - TipRanks
Belite Bio stock target raised to $80 at Benchmark - Investing.com
Belite Bio, Inc. ADR: Promising Clinical Progress and Strong Financial Position Drive Buy Rating - TipRanks
Cantor Fitzgerald Expects Reduced Earnings for Belite Bio - The AM Reporter
Cantor Fitzgerald Forecasts Weaker Earnings for Belite Bio - Defense World
Belite Bio, Inc (NASDAQ:BLTE) Short Interest Up 17.1% in February - Defense World
HC Wainwright Has Pessimistic View of Belite Bio Q1 Earnings - Defense World
Belite Bio (NASDAQ:BLTE) Receives Buy Rating from HC Wainwright - Defense World
Belite Bio’s (BLTE) “Overweight” Rating Reaffirmed at Cantor Fitzgerald - Defense World
Belite Bio’s Earnings Call: Cautious Optimism Amid Progress - TipRanks
Belite Bio Announces 2025 Annual Shareholder Meeting - TipRanks
Belite Bio stock holds $100 target post-results By Investing.com - Investing.com India
Belite Bio stock holds $100 target post-results - Investing.com
Positive Buy Rating for Belite Bio, Inc. Driven by Promising Phase 3 DRAGON Trial Results and Regulatory Prospects - TipRanks
Belite Bio (NASDAQ:BLTE) Shares Gap Down After Earnings Miss - Defense World
Belite Bio Advances in Retinal Disease Trials and Financial Position - TipRanks
Earnings call transcript: Belite Bio ADR Q4 2024 sees steady R&D progress - Investing.com Australia
Belite Bio reports Q4 EPS (32c), consensus (31c) - TipRanks
Belite Bio Reports 2024 Financial Results and Clinical Progress - TipRanks
Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website - Markets Insider
Belite Bio Releases 2024 Annual Report on Website - TipRanks
Belite Bio Reports Positive Interim Analysis Results for Phase 3 DRAGON Trial and Financial Update for Q4 2024 - Nasdaq
Public market insider buying at Savaria (SIS) - The Globe and Mail
Belite Bio's $145M War Chest Powers Critical Phase 3 Eye Disease Trial - StockTitan
Just Released: Belite Bio 2024 Annual Report Reveals Full Year Performance - Stock Titan
Belite Bio (NASDAQ:BLTE) Trading Down 1.6% – Time to Sell? - Defense World
Dry AMD Market Expected to rise, 2034 | Alkeus Pharmaceuticals, Belite Bio, Aviceda Therapeutics, Johnson & Johnson Innovative Medicine, Allegro Ophthalmics, Lineage Cell Therapeutics - The Globe and Mail
Belite Bio to Host Webcast on March 17, 2025, to Discuss Fourth Quarter and Full Year 2024 ... - The Bakersfield Californian
Biotech Pioneer Belite Bio Unveils Q4 and 2024 Performance: Key Retinal Disease Updates Coming March 17 - Stock Titan
Is Meta Platforms Stock a Buy, Sell, or Hold Ahead of Llama 4 Launch? - The Globe and Mail
Parkland Reports Fourth Quarter and Year-End 2024 Results; Initiates Review of Strategic Alternatives - The Globe and Mail
Darwin CX Expands Internationally, Aiming to Tackle Global Publishing Challenges with Locally Tailored Solutions - The Globe and Mail
Can Belite Bio's Retinal Disease Treatments Impress Investors at Upcoming Leerink Conference? - StockTitan
Belite Bio to Participate in the Leerink Partners Global Healthcare Conference - The Globe and Mail
2 Large-Cap Stocks with Exciting Potential and 1 to Avoid - The Globe and Mail
Belite Bio (NASDAQ:BLTE) Shares Gap UpShould You Buy? - MarketBeat
Promising Phase 3 Results for Belite Bio’s Tinlarebant in Stargardt Disease Boost Buy Rating - TipRanks
Belite Bio’s Phase 3 Trial for Stargardt Disease Drug Advances - TipRanks
Belite Bio Announces Interim Analysis Results from the - GlobeNewswire
Can Belite Bio's Tinlarebant Become First Treatment for Stargardt Disease? Phase 3 Data Shows Promise - StockTitan
Belite Bio (NASDAQ:BLTE) Sees Unusually-High Trading VolumeTime to Buy? - MarketBeat
Belite Bio (NASDAQ:BLTE) Sees Unusually-High Trading Volume – Still a Buy? - The AM Reporter
Belite Bio, Inc (NASDAQ:BLTE) Short Interest Down 9.2% in January - MarketBeat
Belite Bio (NASDAQ:BLTE) Stock Price Up 7.8%Should You Buy? - MarketBeat
Finanzdaten der Belite Bio Inc Adr-Aktie (BLTE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.15%
4.32%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):